Noramco Updates Integration of Acquisition of Cambrex’s Drug-Product Business  

Bill Grubb, Vice President, Corporate Development Noramco

Normaco, a CDMO of small-molecule active pharmaceutical ingredients (APIs), recently added drug-product capabilities with the acquisition of the drug-product business of Cambrex. Bill Grubb, Vice President, Corporate Development, Noramco, provided an update at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

Noramco recently announced the formation of the new Noramco Group, a strategic alignment with its API business and the newly acquired Halo Pharma, a drug-product CDMO, from Cambrex, to provide the company the ability to supply both APIs and drug products. With four North American sites employing 900 people, the Noramco Group sites provide clinical to commercial-scale API and drug-product development and manufacturing.  

Noramco, based in Wilmington, Delaware, supplies commercial APIs globally, supporting various medical treatments, such as pain management and drug-abuse treatments. Purisys, located in Athens, Georgia, offers specialized clinical API development and manufacturing services, focusing on controlled substances and pharmaceutical reference standards. Halo Pharma, with operations in Whippany, New Jersey, and Montreal, Quebec, is a CDMO that provides manufacturing services for diverse dosage forms for both brand and generic pharmaceuticals from development through commercialization. Noramco completed the acquisition of the Cambrex drug-product business unit previously known as Halo Pharmaceuticals in February (February 2024).

The acquisition will provide Noramco and its subsidiary, Purisys, additional service options such as drug-product formulation development, clinical and commercial drug-product manufacturing, and packaging from facilities in Mirabel, Québec, and Whippany, New Jersey.